JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...

H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...

JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...

Goldman Sachs reinstated coverage of Esperion (ESPR) with a Neutral rating and $4 price target Post the label expansion, Nexletol and Nexlizet uptake has started to pick up but key opinion leader ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals ...

Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) ...

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Esperion (ESPR) with an Overweight rating and $8 price target. The company markets the oral ATP-citrate lyase inhibitors, Nexletol ...

At the beginning of May, Pfizer spun back out Esperion Therapeutics, which it had originally purchased for $1.3 billion in March 2004. Since the acquisition, most of Esperion's promising pipeline ...

For Dr. JoAnne Foody, the Chief Medical Officer at Esperion, solving this cardiovascular care gap is a personal passion. It’s why she’s excited about Esperion’s recent CLEAR Outcomes study ...

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers ...